Abiraterone acetate: redefining hormone treatment for advanced prostate cancer

详细信息    查看全文

• 作者：Carmel J. Pezaro¹ ; ² ; Deborah Mukherji¹ ; ² ; Johann S. De Bono¹ ; ² ; ^{johann.de-bono@icr.ac.uk} ; ^{jdebono@icr.ac.uk}
• 刊名：Drug Discovery Today
• 出版年：2012
• 出版时间：March, 2012
• 年：2012
• 卷：17
• 期：5-6
• 页码：221-226
• 全文大小：138 K

文摘

Prostate cancer has long since been recognised as being hormonally driven via androgen receptor signalling. Abiraterone acetate (AA) is a rationally designed CYP17 inhibitor that blocks the conversion of androgens from non-gonadal precursors effectively, thus reducing testosterone to undetectable levels. AA has recently been proved to extend survival for men with metastatic castration-resistant prostate cancer who have progressive disease after first-line chemotherapy treatment. In addition, it is currently being tested in a Phase III trial in the pre-chemotherapy setting. This paper will review the preclinical discovery and clinical development of AA and will outline the strategy of parallel translational research.